Precigen Inc
Precigen, Inc.,a discovery and clinical-stage biopharmaceutical company, develops gene and cell therapies using precision technology to target diseases in areas of immuno-oncology, autoimmune disorders, and infectious diseases. It operates through two segments, Biopharmaceuticals and Exemplar. The company offers therapeutic platforms consisting of AdenoVerse platform, which utilizes a library of … Read more
Precigen Inc (PGEN) - Cash Flow Conversion Efficiency
Latest cash flow conversion efficiency as of September 2025: -0.694x
Based on the latest financial reports, Precigen Inc (PGEN) has a cash flow conversion efficiency ratio of -0.694x as of September 2025.
Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-29.07 Million) by net assets ($41.87 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Precigen Inc - Cash Flow Conversion Efficiency Trend (2011–2024)
This chart illustrates how Precigen Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
Precigen Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Precigen Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
CHTC Helon Co Ltd
SHE:000677
|
-0.004x |
|
General Interface Solution GIS Holding Ltd
TW:6456
|
0.052x |
|
MANDARIN ORIENTAL DL-05
F:1C4
|
0.007x |
|
Jupiter Fund Management Plc
PINK:JFHHF
|
0.024x |
|
Bank Sinarmas Tbk
JK:BSIM
|
0.273x |
|
Shanghai Baosteel Packaging
SHG:601968
|
0.070x |
|
CareRay Digital Medical Technology Co Ltd
SHG:688607
|
-0.026x |
|
Petroreconcavo S.A
SA:RECV3
|
0.085x |
Annual Cash Flow Conversion Efficiency for Precigen Inc (2011–2024)
The table below shows the annual cash flow conversion efficiency of Precigen Inc from 2011 to 2024.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $38.51 Million | $-68.17 Million | -1.770x | -213.40% |
| 2023-12-31 | $118.50 Million | $-66.93 Million | -0.565x | -9.64% |
| 2022-12-31 | $126.26 Million | $-65.05 Million | -0.515x | +0.84% |
| 2021-12-31 | $107.35 Million | $-55.77 Million | -0.520x | +54.69% |
| 2020-12-31 | $67.17 Million | $-77.02 Million | -1.147x | -6.75% |
| 2019-12-31 | $71.71 Million | $-77.02 Million | -1.074x | -227.40% |
| 2018-12-31 | $378.72 Million | $-124.24 Million | -0.328x | -72.17% |
| 2017-12-31 | $546.54 Million | $-104.14 Million | -0.191x | -93.77% |
| 2016-12-31 | $569.25 Million | $-55.98 Million | -0.098x | -294.32% |
| 2015-12-31 | $704.89 Million | $35.67 Million | 0.051x | +204.30% |
| 2014-12-31 | $409.29 Million | $-19.86 Million | -0.049x | +65.53% |
| 2013-12-31 | $381.34 Million | $-53.68 Million | -0.141x | -173.57% |
| 2012-12-31 | $-321.55 Million | $-61.53 Million | 0.191x | -48.22% |
| 2011-12-31 | $-221.26 Million | $-81.76 Million | 0.370x | -- |